An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Dapagliflozin tablets 10mg, manufactured by Sun Pharmaceutical Industries Limited, India with Forxiga (Dapagliflozin) film-coated tablets 10 mg, manufactured by AstraZeneca AB Gärtunavägen, SE-151 85 Södertälje Sweden, in healthy adult, human subjects under fasting condition

2023-506408-18-00 Protocol DAPAG-02-23 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 21 Nov 2023 · End 21 Dec 2023 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol DAPAG-02-23

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 48
Countries 1
Sites 1

diabetes

Key facts

Sponsor
Sun Pharmaceutical Industries Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
21 Nov 2023 → 21 Dec 2023
Decision date (initial)
2023-11-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

diabetes

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sun Pharmaceutical Industries Limited

Sponsor organisation
Sun Pharmaceutical Industries Limited
Address
1 Plot No 201 B, Western Express Highway, Goregaon East Western Express Highway Goregaon East
City
Mumbai
Postcode
400063
Country
India

Scientific contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Public contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Ended 48 1
Rest of world 0

Investigational sites

Romania

1 site · Ended
Terapia S.A.
Clinical Pharmacology and Pharmacokinetics, Strada Fabricii Nr 124, 400632, Cuj-Napoca

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Romania 2023-11-21 2023-12-21 2023-11-21 2023-11-25

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-19 Romania Acceptable
2023-11-06
2023-11-09